298 related articles for article (PubMed ID: 19877646)
41. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA.
Gieseg MA; Matejovic J; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):77-84. PubMed ID: 10363030
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
44. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
Hay MP; Wilson WR; Denny WA
Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
[TBL] [Abstract][Full Text] [Related]
45. Antitumor efficacy and molecular mechanism of TLK58747, a novel DNA-alkylating prodrug.
Xu H; Wang Z; Donaldson JC; Yao H; Zhou S; Kelson AB; Ma W; Weber KT; Laborde E; Cheng M; Sambucetti L; Keck JG
Anticancer Res; 2009 Oct; 29(10):3845-55. PubMed ID: 19846918
[TBL] [Abstract][Full Text] [Related]
46. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
Jain M; Kwon CH
J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
[TBL] [Abstract][Full Text] [Related]
47. Two novel nucleoside ester derivatives of chlorambucil as potential antileukemic prodrugs: a preliminary study.
Kryczka T; Kazimierczuk Z; Kozłowska M; Chrapusta SJ; Vilpo L; Vilpo J; Stachnik K; Janisz M; Grieb P
Anticancer Drugs; 2007 Mar; 18(3):301-10. PubMed ID: 17264763
[TBL] [Abstract][Full Text] [Related]
48. Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugs.
Helsby NA; Goldthorpe MA; Tang MH; Atwell GJ; Smith EM; Wilson WR; Tingle MD
Drug Metab Dispos; 2008 Feb; 36(2):353-60. PubMed ID: 17998296
[TBL] [Abstract][Full Text] [Related]
49. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
50. Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.
Tercel M; Atwell GJ; Yang S; Ashoorzadeh A; Stevenson RJ; Botting KJ; Gu Y; Mehta SY; Denny WA; Wilson WR; Pruijn FB
Angew Chem Int Ed Engl; 2011 Mar; 50(11):2606-9. PubMed ID: 21370347
[No Abstract] [Full Text] [Related]
51. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents.
Borch RF; Liu J; Schmidt JP; Marakovits JT; Joswig C; Gipp JJ; Mulcahy RT
J Med Chem; 2000 Jun; 43(11):2258-65. PubMed ID: 10841804
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
54. Synthesis, DNA binding and cytotoxicity of 1-[[omega-(9-acridinyl)amino]alkyl]carbonyl -3-(chloromethyl)-6-hydroxyindolines, a new class of DNA-targeted alkylating agents.
Fan JY; Tercel M; Denny WA
Anticancer Drug Des; 1997 Jun; 12(4):277-93. PubMed ID: 9199660
[TBL] [Abstract][Full Text] [Related]
55. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
56. Bis-benzimidazole anticancer agents: targeting human tumour helicases.
Soderlind KJ; Gorodetsky B; Singh AK; Bachur NR; Miller GG; Lown JW
Anticancer Drug Des; 1999 Feb; 14(1):19-36. PubMed ID: 10363025
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs.
Pedersen PJ; Christensen MS; Ruysschaert T; Linderoth L; Andresen TL; Melander F; Mouritsen OG; Madsen R; Clausen MH
J Med Chem; 2009 May; 52(10):3408-15. PubMed ID: 19402667
[TBL] [Abstract][Full Text] [Related]
58. Enantioselective DNA alkylation by a pyrrole-imidazole S-CBI conjugate.
Bando T; Narita A; Asada K; Ayame H; Sugiyama H
J Am Chem Soc; 2004 Jul; 126(29):8948-55. PubMed ID: 15264825
[TBL] [Abstract][Full Text] [Related]
59. Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs.
Chang JY; Lu GL; Stevenson RJ; Brothers PJ; Clark GR; Botting KJ; Ferry DM; Tercel M; Wilson WR; Denny WA; Ware DC
Inorg Chem; 2013 Jul; 52(13):7688-98. PubMed ID: 23773210
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
Hay MP; Pchalek K; Pruijn FB; Hicks KO; Siim BG; Anderson RF; Shinde SS; Phillips V; Denny WA; Wilson WR
J Med Chem; 2007 Dec; 50(26):6654-64. PubMed ID: 18052317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
